Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Status:
Recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open, single-arm phase I/II clinical study to evaluate the
recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection in Chinese
patients with relapsed/refractory lymphoma .